477871-32-2 Usage
General Description
2-Amino-3-bromo-5-cyanopyridine is a chemical compound with the molecular formula C6H4BrN3. It is a heterocyclic aromatic compound containing a pyridine ring with amino, bromine, and cyano (nitrile) functional groups. 2-Amino-3-bromo-5-cyanopyridine is primarily used in the pharmaceutical and agrochemical industries as an intermediate in the synthesis of various bioactive compounds and pesticides. It is also used in organic synthesis for the development of new drugs and in research for its potential biological and pharmacological properties. 2-Amino-3-bromo-5-cyanopyridine is considered to be a potentially hazardous chemical and must be handled and stored with caution due to its potential health and environmental risks.
Check Digit Verification of cas no
The CAS Registry Mumber 477871-32-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,7,8,7 and 1 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 477871-32:
(8*4)+(7*7)+(6*7)+(5*8)+(4*7)+(3*1)+(2*3)+(1*2)=202
202 % 10 = 2
So 477871-32-2 is a valid CAS Registry Number.
InChI:InChI=1/C6H4BrN3/c7-5-1-4(2-8)3-10-6(5)9/h1,3H,(H2,9,10)
477871-32-2Relevant articles and documents
NITROGENOUS CYCLIC COMPOUND AND COLOR CHANGING FILM COMPRISING SAME
-
Paragraph 0140-0141, (2020/04/10)
The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.
HETEROCYCLIC COMPOUND
-
Paragraph 0783; 0784, (2015/10/28)
The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
NOVEL KINASE INHIBITORS
-
Page/Page column 38, (2008/12/05)
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them usefu